



Diagnosis and Therapeutic Management of Gastrointestinal Cancers

Guest Editors:

Prof. Dr. Christian Sebesta

Klinik Floridsdorf Wiener
Gesundheitsverbund, Vienna,
Austria

Prof. Dr. Harald Rosen

Faculty of Medicine, Sigmund
Freud University, Vienna, Austria

Deadline for manuscript
submissions:

closed (15 May 2023)

Message from the Guest Editors

Dear Colleagues,

Gastrointestinal cancers are showing increasing incidence and mortality rates worldwide and are responsible for 4.8 million new cancer cases and 3.4 million cancer related deaths per year (WHO 2018).

In addition to advances in combinations of conventional chemotherapy with targeted treatment options and upcoming immunotherapy, novel strategies in tumor treatment have yielded remarkable benefits for the patients.

Translational and clinical research introduction of targeted immune and/or chemotherapy regimens as well as advancements in surgical technology (minimal invasive surgery, robotic surgery) have led to a significant reduction of morbidity and shown increasingly promising results in the recent past.

Despite these new advancements, challenges still remain, including regarding issues of preventive measures (e.g., screening for chronic hepatitis, preventive endoscopies, etc.) as well as healthcare and/or reimbursement questions.

This issue will cover the topics related to the diagnosis and therapeutic management of gastrointestinal cancers by presenting reviews and/or meta-analyses as well as recent results from original research.

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)